Stentys has enrolled 500-patients in the APPOSITION III study for its self-apposing stent, used to treat acute myocardial infarction.

Stentys CEO and co-founder Gonzague Issenmann said that study completion demonstrated the growing adoption of self-apposing technology as the solution for treating heart attack patients.

"Given the outstanding clinical results to date and the fast pace of enrolment, we have decided to continue enrolment in order to keep accumulating clinical data," Issenmann added.